Abstracts tagged "Adalimumab and spondylarthritis"

Abstract Number: 1560 • 2017 ACR/ARHP Annual Meeting
Predictors of Long-Term Modified Minimal Disease Activity Response in Peripheral Spondyloarthritis Patients Treated with Adalimumab
Laura C Coates¹, Sonya Abraham², William Tillett³, Philip J Mease⁴, Sofia Ramiro⁵, Tianshuang Wu⁶, Xin Wang⁶, Aileen L. Pangan⁶ and In-Ho Song⁶, ¹University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain, ²NIHR/Wellcome CRF, Imperial College Healthcare NHS Trust, London, United Kingdom, ³Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, United Kingdom, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ⁶AbbVie Inc., North Chicago, IL
Background/Purpose : There is a lack of validated outcome measures in non-psoriatic peripheral spondyloarthritis (pSpA). Therefore, a modified version of the minimal disease activity (mMDA)1…
Abstract Number: 1545 • 2014 ACR/ARHP Annual Meeting
Better Performance of the Leeds and Sparcc Enthesitis Indices Compared to the Mases in Patients with Peripheral Spondyloarthritis during Treatment with Adalimumab
Philip J. Mease¹, Filip van Den Bosch², Joachim Sieper³, Aileen L. Pangan⁴, Nupun A. Varothai⁴ and In-Ho Song⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Ghent University Hospital, Ghent, Belgium, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Peripheral spondyloarthritis (pSpA) is characterized by arthritis, enthesitis, and/or dactylitis. Enthesitis is considered a core outcome domain for SpA; however, there is no clear…
Abstract Number: 2439 • 2013 ACR/ARHP Annual Meeting
Smoking Was Not Associated With Response To Adalimumab Therapy In Patients With Non-Radiographic Axial Spondyloarthritis
Joachim Sieper¹, Denis Poddubnyy², Aileen L. Pangan³, Suchitrita S. Rathmann³ and Jaclyn K. Anderson³, ¹Charité University Medicine Berlin, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³AbbVie Inc., North Chicago, IL
Background/Purpose: Cigarette smoking has been reported as a risk factor for early disease onset, higher disease activity, and poor function in patients (pts) with axial…
Abstract Number: 1801 • 2013 ACR/ARHP Annual Meeting
Relationship Between MRI and Clinical Remission In Patients With Non-Radiographic Axial Spondyloarthritis After Two Years Of Adalimumab Therapy
Désiréé van der Heijde¹, Walter P. Maksymowych², Joachim Sieper³, Robert Lambert⁴, Matthew A. Brown⁵, Suchitrita S. Rathmann⁶, Jaclyn K. Anderson⁶ and Aileen L. Pangan⁶, ¹Leiden University Medical Center, Leiden, Netherlands, ²Medicine, University of Alberta, Edmonton, AB, Canada, ³Charité University Medicine Berlin, Berlin, Germany, ⁴Radiology, University of Alberta Hospital, Edmonton, AB, Canada, ⁵Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ⁶AbbVie Inc., North Chicago, IL
Background/Purpose: Adalimumab (ADA) is currently approved in the EU for the treatment of severe non-radiographic axial spondyloarthritis (nr-axSpA), in patients (pts) with an elevated CRP…
Abstract Number: 1540 • 2013 ACR/ARHP Annual Meeting
Sustained Clinical Remission In Patients With Non-Radiographic Axial Spondyloarthritis After Two Years Of Adalimumab Treatment
Joachim Sieper¹, Dominique L. Baeten², Filip Van den Bosch³, Suchitrita S. Rathmann⁴, Jaclyn K. Anderson⁴ and Aileen L. Pangan⁴, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin-Franklin, Berlin, Germany, ²Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Ghent University Hospital, Ghent, Belgium, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Adalimumab (ADA) is currently approved in the EU for the treatment of severe non-radiographic axial spondyloarthritis (nr-axSpA), in patients (pts) with an elevated CRP…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.